Analyst Research
| Report Title | Price |
|---|---|
|
Provider: Thomson Reuters Stock Report
|
$25.00
|
|
Provider: GlobalData
|
$250.00
|
|
Provider: Reuters Investment Profile
|
$20.00
|
|
Provider: Reuters Investment Profile
|
$20.00
|
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
NanoCarrier Co., Ltd. and Eisai Co., Ltd. to Cooperate in Drug Research
NanoCarrier Co., Ltd. announced that NanoCarrier Co., Ltd. and Eisai Co., Ltd. have signed a co-development contract, regarding the research and development of a drug. The details regarding the drug are not disclosed.
Latest Developments for Eisai Co Ltd
- EU Regulatory Authorities Grant Orphan Status To Eisai Co Ltd's Lenvatinib For Treatment Of Radioiodine-Refractory Differentiated Thyroid Cancer
- Eisai Co Ltd Announces Results of Phase III Study of Anticancer Agent Farletuzumab in Patients with Relapsed Platinum-Sensitive Ovarian Cancer
- Eisai Co Ltd to Dissolve Subsidiary-Yakuji Nippo
- Eisai Co Ltd Receives Approval for Halaven in South Korea and Australia – Yakuji Nippo
Latest Key Developments in Pharmaceuticals
- Nattopharma ASA Maintains FY 2013 Revenue Guidance
- Grifols SA’s Study Demonstrates Higher Dose Of PROLASTIN-C Increases Levels Of Alpha1-PI To Within Normal Range In Patients With AAT Deficiency-DJ
- Protalex Inc Announces Positive Interim Review of Phase 1b Trial Of PRTX-100 in Rheumatoid Arthritis By Independent Data Safety Monitoring Committee
- Pfizer Inc Announces Plan For Split-Off Of Zoetis Inc
- Share this
- Link this
- Digg this
Follow Reuters